慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是一种罕见的由免疫介导的脱髓鞘性周围神经病 1 。CIDP患者会经历一系列的行动和感觉问题，包括从坐姿站起来困难、疼痛和疲劳、经常绊倒或摔倒。随着疾病进展，许多患者需依赖轮椅且无法工作，对患者造成 ...

慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是常见的慢性免疫介导的周围神经病。早期准确诊断对于及时治疗和预防不可逆的神经病变具有重要价值。为深入探讨CIDP诊疗现状和进展，共话解决之策，由北京整合医学学会主办的“神经免疫疾病学术交流会 ...

一名44岁的复发性/难治性CIDP男性患者表现出肢体远端麻木和无力。根据 2021 年欧洲神经病学学会/外周神经病学学会 CIDP 指南 ...

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...

日本大阪和马萨诸塞州剑桥--(BUSINESS WIRE)--(美国商业资讯)-- Takeda(TSE:4502/NYSE:TAK)今天公布了3期ADVANCE-CIDP 3临床试验的数据，这是 ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and ...

CIDP是一种罕见的自身免疫介导多发性神经病变，静脉给药免疫球蛋白(IVIg)是最常用的一线治疗药物。 2021年02月16日讯 /生物谷 ...

Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA ® [Immune Globulin Infusion 10% ...

Favorable Findings fromthe Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for Maintaining Stable Disease Course in CIDP ADVANCE Clinical Program ...